Lung Cancer Clinical Trial
Official title:
A Phase II Study of Single Agent Sorafenib in Non-small Cell Lung Cancer Patients Who Never Smoked or Were Former Light Smokers.
Verified date | February 2019 |
Source | Ohio State University Comprehensive Cancer Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth and by blocking blood flow to the tumor.
PURPOSE: This phase II trial is studying how well sorafenib works in treating non-smokers or
former light smokers with relapsed or refractory stage IIIB or stage IV non-small cell lung
cancer.
Status | Terminated |
Enrollment | 11 |
Est. completion date | April 2012 |
Est. primary completion date | April 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
DISEASE CHARACTERISTICS: - Histologically confirmed non-small cell lung cancer - Stage IIIB or IV disease - Recurrent disease after prior surgery, chemotherapy, or radiotherapy - No squamous cell histology or mixed tumor with > 50% squamous cells - Non-smoker (smoked = 100 cigarettes in lifetime) OR former light smoker (smoked > 100 cigarettes but = 10 pack years AND quit smoking = 1 year ago) - No known brain metastasis - Patients with neurological symptoms must undergo a CT scan or MRI of the brain to exclude brain metastasis PATIENT CHARACTERISTICS: - ECOG(Eastern Cooperative Oncology Group)performance status 0-2 - ANC (Absolute Neutrophil Count)= 1,500/mm³ - Platelet count = 100,000/mm³ - ALT (Alanine Aminotransferase Test) and AST (Aspartate Aminotransferase Test) = 2.5 times upper limit of normal (ULN) - Alkaline phosphatase = 2.5 times ULN - Bilirubin = 1.5 mg/dL - Creatinine clearance = 50 mL/min - INR (International Normalized Ratio) < 1.5 OR PT/PTT (Prothrombin time/partial thromboplastin time)normal - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective barrier contraception prior to, during, and for = 3 months after completion of study treatment - No cardiac disease, including any of the following: - New York Heart Association class III-IV congestive heart failure - Unstable angina (anginal symptoms at rest) - New-onset angina within the past 3 months - Myocardial infarction within the past 6 months - No cardiac ventricular arrhythmias requiring anti-arrhythmic therapy - No uncontrolled hypertension (i.e., systolic blood pressure [BP] > 150 mm Hg or diastolic BP > 90 mm Hg) despite optimal medical management - No thrombolic or embolic events (e.g., cerebrovascular accident, including transient ischemic attacks) within the past 6 months - No pulmonary hemorrhage or bleeding event = CTCAE (Common Terminology Criteria for Adverse Events)grade 2 within the past 4 weeks - No other hemorrhage or bleeding event = CTCAE grade 3 within the past 4 weeks - No active clinically serious infection > CTCAE grade 2 - No serious non-healing wound, ulcer, or bone fracture - No evidence or history of bleeding diathesis or coagulopathy - No known HIV infection or chronic hepatitis B or C - No other malignancy except for any of the following: - Adequately treated basal cell or squamous cell skin cancer - In situ cervical cancer - Other cancer from which the patient has been disease-free for = 5 years with a low probability of recurrence - No condition that impairs the patient's ability to swallow whole pills - No malabsorption problems - No known or suspected allergy to sorafenib tosylate or any agent given in the course of this study - No significant traumatic injury within the past 4 weeks PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No more than one prior systemic chemotherapy treatment for metastatic disease - Prior treatment with EGFR inhibitors is not considered chemotherapy - More than 4 weeks since prior major surgery or open biopsy - No prior sorafenib tosylate - No concurrent St. John's wort or rifampin - Concurrent anticoagulation with warfarin or heparin allowed |
Country | Name | City | State |
---|---|---|---|
United States | Ohio State University | Columbus | Ohio |
Lead Sponsor | Collaborator |
---|---|
Ohio State University Comprehensive Cancer Center | Bayer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression-free Survival at 6 Months | Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions", or similar definition as accurate and appropriate | 6 months | |
Secondary | Overall Survival Rate | Determine the one year survival rate in Non/Light smokers with advanced and previouslytreated NSCLC | Up to 2 years | |
Secondary | Incidence of Adverse Events Sssessed by Common Terminology Criteria for Adverse Events (CTCAE) | Assess the frequency and severity of adverse events associated with Sorafenib in this patient population Non/Light smokers with advanced and previously treated NSCLC. | Up to 2 years | |
Secondary | Mutational Status for EGFR or Kras | up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|